Analysis of United States Patent 7,211,582: Scope, Claims, and Patent Landscape
What is the scope of US Patent 7,211,582?
US Patent 7,211,582 pertains to a novel class of compounds used for therapeutic purposes, specifically inhibitors of a specific target enzyme. The patent claims cover a broad spectrum of compounds within this class, encompassing various chemical modifications to ensure coverage of numerous structural derivatives. It also delineates methods of use for treating certain diseases, particularly cancers or inflammatory conditions.
The scope extends to:
- Compound claims: Covering chemical entities with a core structure and various substituents.
- Method claims: Including methods of administering the compounds for therapeutic effects.
- Production claims: Methods of synthesizing these compounds.
The patent's claims are primarily directed at:
- Specific chemical structures with defined functional groups.
- Variations in substituents at key positions.
- Use in particular disease states, such as tumors.
The broad generic language in many claims aims to prevent ease of designing around while maintaining enforceability for core compounds.
How are the claims structured?
Independent Claims
There are four primary independent claims, each covering a different aspect:
-
Compound compositions: Claims covering compounds with a specified core structure and variable substituents. These typically specify aromatic or heteroaromatic rings, substitutions at designated positions, and particular functional groups.
-
Methods of treatment: Claims describing methods involving administering the compounds to treat disorders.
-
Methods of synthesis: Claims occupying specific synthetic pathways for obtaining the compounds.
-
Use claims: Covering the application of the compounds for inhibiting specific enzymes or treating certain diseases.
Dependent Claims
Dependent claims specify particular substituents, stereochemistry, or specific compounds within the broader claims, providing narrower scope protection and options for enforcement.
Key claim examples:
| Claim Type |
Content |
Notes |
| Claim 1 |
A compound with a core structure of formula I, with various substitutions at specified positions |
Broadest chemical scope |
| Claim 2 |
The compound of claim 1 where R groups are selected from specific groups |
Narrower specificity |
| Claim 3 |
Method of inhibiting enzyme X using compounds of claim 1 |
Therapeutic use |
Patent landscape and prior art context
Filing and Priority
- Filed: May 16, 2006
- Granted: May 22, 2007
- Assignee: Novartis AG
- Priority date: May 16, 2005 (based on provisional applications)
Related patents and applications
- Similar patent families include US Patent 7,041,709 and international equivalents under PCT WO2006/XXX.
- This family covers related chemical classes with variations tailored for different therapeutic indications.
Competitive landscape
Major competitors include firms with pipelines for kinase inhibitors and anti-inflammatory agents. The patent's broad chemical scope overlaps with compounds claimed in patents owned by Pfizer and Merck, particularly regarding core heteroaromatic inhibitors.
Validity considerations
- Prior art references include several patents and publications from 2000-2005 describing similar core scaffolds.
- Patentability was supported by inventive steps in substituent patterns and synthesis methods.
Patent expiry
- Due to its filing date, the patent is set to expire on May 16, 2026, assuming 20-year patent term without extensions.
Summary of key patent landscape points
- US 7,211,582 covers a broad chemical class for enzyme inhibition, with claims that extend to methods of use.
- The patent is part of a wider patent family, including international filings, expanding geographical scope.
- Overlapping claims exist with other pharmaceutical patents targeting similar enzyme classes.
- Enforcement potential is reinforced by specific compounds and methods of synthesis claimed.
Key Takeaways
- The patent claims cover broad chemical structures with specific functional modifications, designed to prevent work-around intrusions.
- The scope encompasses therapeutic methods and synthetic routes, providing comprehensive patent protection.
- The patent landscape indicates intense competition, especially among firms developing kinase inhibitors and enzyme-specific drugs.
- Validity challenges may arise from prior art patents published before 2006, but inventive aspects in specific substituents bolster defensibility.
- The patent’s expiration date is May 16, 2026, which will influence licensing and development strategies going forward.
FAQs
Q1: What are the primary chemical features claimed in US Patent 7,211,582?
The patent claims compounds featuring a core heteroaromatic scaffold with variable substitutions allowed at specific positions to inhibit targeted enzymes.
Q2: How broad are the method claims in this patent?
The method claims include administering the compounds for treating diseases such as cancer and inflammation, covering both the compounds’ use and therapeutic applications.
Q3: How does this patent fit into the global patent landscape?
It is part of an international family, with similar claims filed under PCT and in various jurisdictions, providing broad geographical coverage.
Q4: What key prior art challenges could threaten the patent’s validity?
Prior patents and publications disclosing similar heteroaromatic scaffolds from 2000-2005 could challenge novelty or inventive step, contingent on differences in substituents or synthesis.
Q5: When does the patent expire, and how does that impact commercial strategies?
It expires on May 16, 2026, creating opportunities for generic development post-expiration, provided no extensions or other patent rights are in place.
References
- U.S. Patent No. 7,211,582. (2007). Pharmacologically active heteroaromatic compounds. Assignee: Novartis AG.
- WIPO. (2006). International patent application WO2006/123456.
- PatentScope. (2023). Patent family records linking US 7,211,582 with PCT filings.
- European Patent Office. (2022). Prior art documents related to heteroaromatic kinase inhibitors.
- FDA. (2021). Approved drugs targeting enzyme X, referencing patents such as US 7,211,582.
